A buried provision in New Jersey's A4852 has quietly changed how behavioral health and telehealth practices can initiate stimulant treatment—and it reshapes your patient workflow.
Most health service owners in New Jersey don't realize that as of June 23, 2026, they can now prescribe Schedule II stimulants—including ADHD medications—to adult patients entirely via telehealth without requiring a prior in-person visit. This change, buried in bill A4852, directly affects how small telehealth practices, behavioral health clinics, and psychiatric providers can onboard and treat patients. Understanding it matters for your scheduling, compliance, and patient-acquisition strategy.
New Jersey amended C.45:1-62, subsection e(4), to permit telehealth and telemedicine providers to initiate prescriptions for Schedule II controlled substances—primarily stimulants used for ADHD—without an in-person examination first. Previously, state law required an established provider-patient relationship and an in-person visit before any controlled-substance prescription could be written remotely.
The new rule allows a licensed prescriber to conduct an initial telehealth-only encounter, assess the patient, and issue a stimulant prescription without that patient ever having walked into your office. The catch: you must schedule an in-person visit within 30 days of that first telehealth appointment, and then annually thereafter to maintain the prescription.
This applies to any New Jersey health service that prescribes Schedule II stimulants—chiefly ADHD medications like methylphenidate, amphetamine, and related compounds—to adult patients via telehealth or telemedicine. Behavioral health practices, psychiatric clinics, primary-care telehealth platforms, and independent prescribers all fall under this change.
It does not apply to in-person-only practices or those that don't prescribe controlled substances. It also does not change requirements for pediatric patients or non-stimulant medications.
Patient acquisition: You can now convert a telehealth inquiry into a prescription without scheduling an office visit first. This lowers the barrier to entry for patients seeking ADHD treatment and can increase initial conversion rates.
Scheduling infrastructure: You must now track and enforce a 30-day in-person follow-up window for every stimulant patient acquired via telehealth-only intake. Missing this deadline could expose you to compliance risk. Your scheduling system needs to flag these appointments automatically.
Compliance obligation: Annual in-person visits are now a legal requirement to continue prescribing. This is not optional. Document each visit and tie it to the prescription record.
Workflow redesign: Your intake process, clinical assessment forms, and follow-up protocols may need revision to account for telehealth-first onboarding and the mandatory in-person checkpoints.
This provision took effect immediately upon enactment on June 23, 2026, under Section 2 of A4852. If you are currently requiring in-person visits before stimulant prescribing, you are operating under the old standard and may be unnecessarily limiting your patient reach.
Health service owners should review their current telehealth protocols, update their compliance checklists, and ensure staff understand the 30-day and annual in-person visit requirements. A detailed, practice-specific compliance guide is available for free download through your state trade association.
Source: New Jersey Assembly Bill A4852, Section 1, amending N.J.S.A. C.45:1-62, subsection e(4); effective June 23, 2026.